Ares Trading SA

Ares Trading SA specializes in insulin delivery solutions, including pre-filled insulin pens (such as aluetta 6mg and 20mg), insulin pumps (like easypod, easypod 2, and easypod 3), and insulin injection aids (such as Rebiject II). They also offer smart insulin management systems, including RebiSmart and RebiSmart 3.0. These devices are designed to assist patients in managing diabetes through precise insulin administration.

Ares Trading SA is based in Switzerland, which is within the European Economic Area (EEA). This positioning allows the company to comply with EU Medical Device Regulations (MDR) directly, ensuring its devices are listed in the EUDAMED database—a central registry for medical devices authorized in the EU. The company’s location also facilitates adherence to Swiss regulatory standards, though its devices are primarily governed by EU requirements when marketed in the EU.

Ares Trading SA’s devices are listed in the EUDAMED database, the official European Union registry for medical devices. This registry is mandated under the EU Medical Device Regulations (MDR) to ensure transparency and traceability of authorized devices across the EU market. Listing in EUDAMED confirms that these devices have undergone the necessary conformity assessments and meet EU safety, performance, and regulatory requirements before being placed on the market.

Ares Trading SA’s devices fall under Class I and Class IIa classifications according to the EU Medical Device Regulations. Class I devices are generally low-risk, such as some insulin pens or simple injection aids, while Class IIa devices—like certain insulin pumps or smart management systems—pose moderate risks and require additional scrutiny, including clinical evaluations or performance studies, to ensure safety and efficacy before authorization.

Checking EUDAMED confirms that a device has been authorized for sale in the EU, meaning it has met the required regulatory standards for safety, quality, and performance. This registry helps healthcare providers and patients verify that the device is legally marketed, reducing risks of counterfeit or non-compliant products. For insulin delivery devices, this is particularly important due to their critical role in managing chronic conditions like diabetes.